DK0662130T3 - Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje - Google Patents

Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje

Info

Publication number
DK0662130T3
DK0662130T3 DK93921471T DK93921471T DK0662130T3 DK 0662130 T3 DK0662130 T3 DK 0662130T3 DK 93921471 T DK93921471 T DK 93921471T DK 93921471 T DK93921471 T DK 93921471T DK 0662130 T3 DK0662130 T3 DK 0662130T3
Authority
DK
Denmark
Prior art keywords
met
hgf
preparation
antibody
substance
Prior art date
Application number
DK93921471T
Other languages
Danish (da)
English (en)
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0662130T3 publication Critical patent/DK0662130T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK93921471T 1992-09-18 1993-09-15 Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje DK0662130T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18
PCT/US1993/008531 WO1994006909A2 (en) 1992-09-18 1993-09-15 A method of preventing tumor metastasis

Publications (1)

Publication Number Publication Date
DK0662130T3 true DK0662130T3 (da) 1998-08-10

Family

ID=25483898

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93921471T DK0662130T3 (da) 1992-09-18 1993-09-15 Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje

Country Status (10)

Country Link
EP (2) EP0662130B1 (el)
JP (2) JP3553936B2 (el)
AT (2) ATE160585T1 (el)
AU (1) AU675968B2 (el)
CA (1) CA2144856A1 (el)
DE (2) DE69315440T2 (el)
DK (1) DK0662130T3 (el)
ES (1) ES2112997T3 (el)
GR (1) GR3026165T3 (el)
WO (1) WO1994006909A2 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
CA2144081C (en) * 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
CA2270867A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
WO2000025727A2 (en) * 1998-11-04 2000-05-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
WO2001034650A1 (en) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
AU2001277854B2 (en) * 2000-06-29 2007-03-01 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN104804095A (zh) 2004-08-05 2015-07-29 健泰科生物技术公司 人源化抗c-met 拮抗剂
TWI362940B (en) 2005-03-31 2012-05-01 Gen Hospital Corp A use of agonist and/or antagonist of hgf/hgfr activity
RU2403261C2 (ru) 2005-04-15 2010-11-10 Дженентек, Инк. Варианты бета-цепи hgf
CA2646620C (en) 2006-03-20 2015-07-14 Seikagaku Corporation Therapeutic agent for rheumatoid arthritis
CN101415730B (zh) 2006-03-30 2013-04-10 诺瓦提斯公司 c-Met抗体的组合物和使用方法
EP2545077B1 (en) 2010-03-10 2018-10-31 Genmab A/S Monoclonal antibodies against c-met
AU2011325097B2 (en) 2010-11-03 2015-05-21 Argenx Bvba Anti c-Met antibodies
CA2832113C (en) * 2011-04-02 2020-07-21 Washington State University Research Foundation Hepatocyte growth factor mimics as therapeutic agents
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
BR112017005202A2 (pt) 2014-09-16 2017-12-12 Symphogen As anticorpos anti-met e composições

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
AU650292B2 (en) * 1990-09-14 1994-06-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A non-mitogenic competitive HGF antagonist
JPH07508420A (ja) * 1992-05-18 1995-09-21 ジェネンテク，インコーポレイテッド 肝細胞成長因子変異体

Also Published As

Publication number Publication date
JP3553936B2 (ja) 2004-08-11
ES2112997T3 (es) 1998-04-16
AU4855593A (en) 1994-04-12
WO1994006909A2 (en) 1994-03-31
EP0805203B1 (en) 2007-08-01
DE69315440T2 (de) 1998-07-09
GR3026165T3 (en) 1998-05-29
JP2004002440A (ja) 2004-01-08
EP0662130A1 (en) 1995-07-12
JPH08504093A (ja) 1996-05-07
DE69315440D1 (de) 1998-01-08
DE69334159D1 (de) 2007-09-13
ATE368738T1 (de) 2007-08-15
ATE160585T1 (de) 1997-12-15
CA2144856A1 (en) 1994-03-31
EP0805203A1 (en) 1997-11-05
AU675968B2 (en) 1997-02-27
WO1994006909A3 (en) 1994-05-26
EP0662130B1 (en) 1997-11-26

Similar Documents

Publication Publication Date Title
DK0662130T3 (da) Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje
DE69433406D1 (de) Antikörper gegen cd40
NO2017038I2 (no) Adalimumab - Forlenget SPC
MY145191A (en) Human antibodies that bind human il-12 and methods for producing
DE69233482D1 (de) Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69427869T2 (de) Botulinumtoxine zur behandlung von hyperhydrosis
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
DE69328928D1 (de) Varianten in den leltin domäne von selektin
ATE162553T1 (de) Monoklonale antikörper gegen hepatitis-c-virus
DK0504307T3 (da) Fremgangsmåde til behandling af septisk shock
DK361282A (da) Fremgangsmaade til fremstilling af o-alkyl-o-carbamoylglycerophosphocholiner
DE69527868T2 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
DE60020729D1 (de) Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
DK119891D0 (da) Forbedringer ved og i forbindelse med magnetisk resonansafbildning
ES2053704T3 (es) Un metodo de estabilizacion de una composicion acuosa consistente en uno o mas anticuerpos monoclonales.
DE69112392D1 (de) Bcrf1-antagonisten zur behandlung von epstein-barr-virus-infektionen.
Durand-Charre et al. Structure and Solidification Sequence of Alloyed White Cast Irons.(Synopsis)
DK159280A (da) Fremgangsmaade til styring af kontrasten ved reproduktion saasom rasterreproduktion
ES2030342A6 (es) Procedimiento de obtencion de una fuente de antigeno para el serodiagnostico inmunohistologico de la listerioris.
DK26393D0 (da) Fremgangsmaade til overfladebehandling af isaer graat staabejern
DE68901234D1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.